June 21, 2024
Global Dupuytrens Disease Market

Global Dupuytrens Disease Market is Estimated to Witness High Growth Owing to Increasing R&D Investments by Key Players

Dupuytren’s disease is a condition in which one or more fingers become permanently bent in a flexed position. This condition occurs due to the formation of fibrous cords in the hand. As the disease progresses it can cause the fingers to bend progressively more until they become fixed in a bent position. The current treatment options include needle fasciotomy, collagenase injections, and surgery. Dupuytren’s disease condition mostly affects men over 60 years. The increasing prevalence of Dupuytren’s disease globally is expected to drive the growth of the global Dupuytren’s disease market during the forecast period.

The Global Dupuytren’s disease Market is estimated to be valued at US$ 4.3 Bn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2024 To 2031.

Key Takeaways

Key players: Key players operating in the Dupuytren’s disease market are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp.

Key players operating in the Global Dupuytrens Disease Market Trends are focusing on increasing research and development activities to develop advanced and novel treatment options for Dupuytren’s disease. For instance, in 2020, 180 Life Sciences Corp initiated a Phase 2b/3 clinical trial to investigate the safety and efficacy of their collagenase XYOSTED injection for treating early-stage Dupuytren’s disease.

Key opportunities: Rising prevalence of Dupuytren’s disease globally due to increasing geriatric population and lifestyle changes presents lucrative opportunities for players in the market. Development of advanced non-surgical treatment options also presents an opportunity for emerging players.

Global expansion: Major players are focusing on expansion in emerging economies of Asia Pacific and Latin America. Increasing awareness about disease condition and improving healthcare infrastructure in developing countries will propel the demand for Dupuytren’s disease treatment over the forecast period.

Market drivers: Increasing research and development investments by key players for developing novel therapies is expected to be a major market driver. Rising geriatric population globally which is more prone to Dupuytren’s disease will further fuel the market growth. Growing awareness about Dupuytren’s disease condition and availability of various treatment options is also driving the market.

PEST Analysis

Political: The approval procedures for treatments are regulated by government bodies like the FDA in the US and EMA in Europe. Changes in healthcare policies could impact market growth.

Economic: As disposable incomes rise globally, patients are able to spend more on specialty treatments. However, economic slowdowns may limit healthcare budgets and affect market revenues.

Social: With increasing lifestyle-related disorders, awareness about Dupuytren’s contracture is growing. This is boosting the demand for effective therapies.

Technological: Scientists are researching advanced drug delivery systems and regenerative medicine techniques for better management of the condition without surgery. Use of stem cells and gene therapy holds promise.

The market is currently led by North America and Europe owing to sophisticated healthcare infrastructure and high patient awareness in these regions. Large patient populations, rising disease prevalence due to risk factors like diabetes, and growing medical tourism are driving the market in Asia Pacific and Latin America.

The Middle East and Africa present significant scope for future market expansion. Economic growth in countries like Saudi Arabia and South Africa is improving access to healthcare. Additionally, governments are promoting foreign investments and partnerships to enhance local medical capabilities. This is set to boost the adoption of Dupuytren’s disease treatments in the African region during the forecast period.

*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.